INVESTIGATIONAL PIPELINE A POWERFUL RESEARCH AND DEVELOPMENT ENGINE
Our pipeline is powered by end-to-end research and development capabilities. The Research team discovers promising new drug compounds. From there, Global Development brings these investigational candidates through the full clinical development process, from trial design to study execution and lifecycle management. Our product portfolio reflects the true collaborative spirit of Regeneron.
Phase 1
-
ALN-APP1
APP RNAi Therapeutic Early-onset Alzheimer’s disease
Neurology General Medicine -
ALN-HSD1
HSD17B13 RNAi Therapeutic Nonalcoholic steatohepatitis ("NASH")
Immunology & Inflammation General Medicine -
FIANLIMAB
LAG-3 Antibody Solid tumors, advanced hematologic malignancies
Oncology Hematology -
LINVOSELTAMAB
BCMA X CD3 Antibody Multiple myeloma
Hematology -
"NEXT GENERATION" COVID ANTIBODIES
Antibodies to SARS-CoV-2 Variants Healthy volunteers
Infectious Diseases General Medicine -
NTLA-20013
TTR gene knockout using CRISPR/Cas9 Transthyretin ("ATTR") amyloidosis
Rare Diseases Hematology -
ODRONEXTAMAB
CD20 X CD3 Antibody Certain B-cell malignancies
Oncology Hematology -
REGN4336
PSMA X CD3 Antibody Prostate cancer
Oncology -
REGN5093
MET X MET Antibody MET-altered advanced NSCLC
Oncology -
REGN5093-M114
MET X MET Antibody MET overexpressing advanced cancer
Oncology -
REGN5381/REGN9035
Agonist Antibody to NPR1/Reversal Agent to REGN5381 Reversal agent in healthy volunteers
General Medicine -
REGN5459
BCMA X CD3 Antibody Transplant desensitization in patients with chronic kidney disease
Oncology Hematology -
REGN5668
MUC16 x CD28 Antibody Platinum-resistant ovarian cancer
Oncology -
REGN5678
PSMA X CD28 Antibody Prostate cancer
Oncology -
REGN6569
GITR Antibody Solid tumors
Oncology -
REGN7075
EGFR x CD28 Antibody Solid tumors
Oncology -
REGN7257
IL-2Rg Antibody Aplastic anemia
Hematology -
REGN7999
TMPRSS6 Antibody Transfusion dependent iron overload
Hematology -
REGN9933
Factor XI Antibody Thrombosis
Hematology
Phase 2
-
CEMDISIRAN1
C5 siRNA Therapeutic Immunoglobulin A nephropathy
Rare Diseases Hematology -
CEMIPLIMAB
PD-1 Antibody Metastatic or locally advanced CSCC, neoadjuvant CSCC, second-line cervical cancer ISA101b combination
Oncology -
DUPILUMAB5
IL-4R alpha subunit Antibody Grass allergy
Immunology & Inflammation -
LINVOSELTAMAB
BCMA X CD3 Antibody Multiple myeloma (potentially pivotal study)
Oncology Hematology -
MIBAVADEMAB
Leptin receptor ("LEPR") Agonist Antibody Generalized lipodystrophy, partial lipodystrophy
Rare Diseases General Medicine -
ODRONEXTAMAB
CD20 X CD3 Antibody B-cell non-Hodgkin lymphoma ("B-NHL") (potentially pivotal study)
Oncology Hematology -
POZELIMAB
C5 Antibody CD55-deficient protein-losing enteropathy, monotherapy (potentially pivotal study)
Rare Diseases Hematology -
REGN5381/REGN9035
Agonist Antibody to NPR1/Reversal Agent to REGN5381 Heart failure
General Medicine -
SARILUMAB5
IL-6R Antibody Polyarticular-course juvenile idiopathic arthritis ("pcJIA"), systemic juvenile idiopathic arthritis ("sJIA")
Immunology & Inflammation -
UBAMATAMAB
MUC16 X CD3 Antibody Platinum-resistant ovarian cancer
Oncology -
VIDUTOLIMOD
TLR9 Immune Activator CSCC and Merkel cell carcinoma
Oncology
Phase 3
-
AFLIBERCEPT 8MG2
VEGF-Trap Wet AMD, DME
Ophthalmology -
AFLIBERCEPT2
VEGF-Trap ROP
Ophthalmology -
ALIROCUMAB
PCSK9 Antibody HeFH in pediatrics
General Medicine -
CEMIPLIMAB5
PD-1 Antibody First-line NSCLC chemotherapy combination, second-line cervical cancer, adjuvant CSCC
Oncology -
DUPILUMAB5
IL-4R alpha subunit Antibody EoE in pediatrics; chronic obstructive pulmonary disease ("COPD"); bullous pemphigoid (Phase 2/3); chronic spontaneous urticaria ("CSU"); chronic inducible urticaria - cold; chronic rhinosinusitis without nasal polyposis; allergic fungal rhinosinusitis; chronic pruritis of unknown origin
Immunology & Inflammation -
FIANLIMAB
LAG-3 Antibody First-line metastatic melanoma
Oncology -
GARETOSMAB
Activin A Antibody Fibrodysplasia ossificans progressiva ("FOP")
Rare Diseases General Medicine -
ITEPEKIMAB5
IL-33 Antibody COPD
Immunology & Inflammation -
POZELIMAB + CEMDISIRAN1
C5 Antibody + C5 siRNA Therapeutic Myasthenia gravis cemdisiran combination, paroxysmal nocturnal hemoglobinuria ("PNH") cemdisiran combination
Rare Diseases Hematology -
REGN5713-5714-5715
Bet v 1 Multi-Antibody Therapy Birch allergy
Immunology & Inflammation
No results found. Please adjust your filter selection and try again.
1In collaboration with Alnylam
2In collaboration with Bayer outside of the U.S.
3In collaboration with Intellia
4In collaboration with Roche outside of the U.S.
5In collaboration with Sanofi
This graphic displays pipeline drug candidates currently undergoing clinical testing in a variety of diseases. The safety and efficacy of these drug candidates have not been fully evaluated by any regulatory authorities for the indications described in this section.
Scientific trailblazers
Following the science leads to unexpected breakthroughs and diverse areas of study —from ophthalmology to cancer to inflammation to pain to cardiovascular disease.
Our Current Research
Explore our clinical trials
The discoveries never stop as we work to help people with serious diseases. Clinical trials allow us to carefully test and collect data about investigational products before they can be approved for use. Learn more about our clinical trials or find a relevant one near you.
Find Trialsto top